Supernus Pharmaceuticals (SUPN) Free Cash Flow (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Free Cash Flow data on file, last reported at $66.5 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at $66.5 million, up 119.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.2 million (down 49.65% YoY), and the FY2025 annual result was $46.0 million, down 73.14% from the prior year.
• Free Cash Flow rose to $66.5 million in Q1 2026 per SUPN's latest filing, from $19.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $71.4 million in Q2 2022 and troughed at -$61.8 million in Q3 2025.
• A 5-year average of $30.0 million and a median of $35.7 million in 2023 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow surged 1201.57% in 2023, then sank 215.89% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $27.7 million in 2022, then surged by 62.25% to $45.0 million in 2023, then slipped by 1.78% to $44.2 million in 2024, then tumbled by 56.02% to $19.4 million in 2025, then soared by 242.31% to $66.5 million in 2026.
• Business Quant data shows SUPN's Free Cash Flow at $66.5 million in Q1 2026, $19.4 million in Q4 2025, and -$61.8 million in Q3 2025.